Navigation Links
Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study,Presented at ASCO

Safety and Single-Agent Activity Support Development of Panzem(R) NCD as a Combination Therapy for Glioblastoma Multiforme

ROCKVILLE, Md., June 05, 2007 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announces the presentation of results of a single-agent Phase 2 study for Panzem(R) NCD (2ME2) in patients with glioblastoma multiforme (GBM). The data were presented by David A. Reardon, M.D., Associate Deputy Director at The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center and principal investigator for the study, at the American Society of Clinical Oncology (ASCO) Annual Meeting underway in Chicago.

The single-agent, open-label study, conducted at Duke University, was designed to assess the safety, pharmacokinetics and efficacy of Panzem(R) NCD in patients with recurrent GBM who have failed initial therapies. Of the 27 patients enrolled in this study, 78% had received two or more prior cancer agents. Results from this Phase 2 study included one partial response and seven stable diseases. Panzem(R) NCD was well-tolerated with reversible transaminase elevations as the only grade 3 toxicity in more than one patient, and no grade 4 toxicities.

Commenting on the results of the study, Dr. Reardon said, "Panzem(R) NCD was generally well-tolerated and showed modest activity as a single agent. This study and prior preclinical studies support the hypothesis that Panzem(R) NCD could be used in combination with an approved chemotherapeutic agent such as temozolomide (Temodar(R)) in GBM patients to potentially improve outcome further. The Duke University Brain Tumor Center has recently initiated a Phase 2 study of the Panzem(R) NCD/Temodar(R) combination."

Carolyn F. Sidor, M.D., MBA, EntreMed Vice President and Chief Medical Officer, commented, "Our clinical developme
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/19/2014)... Larry J. Merlo , President and CEO of CVS ... National Press Club in Washington, D.C. ... selling tobacco products and its leadership in driving the innovations ... changes in our health care system pose enormous challenges to ... "CVS Health has a truly unique combination of business assets ...
(Date:9/19/2014)... WALTHAM, Mass. , Sept. 19, 2014  Alere ... in rapid diagnostics, issued the following statement today in ... Combating Antibiotic-Resistant Bacteria. "As the global leader ... President for establishing a national strategy to address the ... continuing to work with the Administration on initiatives to ...
(Date:9/19/2014)... DIEGO , Sept. 19, 2014  Lpath, ... leader in bioactive lipid-targeted therapeutics, announced today that ... 3,605,042 registered shares of common stock and 3,605,042 ... combined purchase price for one registered share of ... one unregistered share of common stock will be ...
Breaking Medicine Technology:CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
... PLEASANTON, Calif., Dec. 2 Roche (SIX: RO, ROG; OTCQX: ... Administration (FDA) approved an additional intended use for its licensed ... of up to 96 individual donations. The test, called the ... s 201 system, is a qualitative, in-vitro test for ...
... , NANJING, China, Dec. 2 ... SCR ), a leading pharmaceutical company,specializing in ... pharmaceuticals in China, today reported that its,subsidiary Jiangsu Yanshen ... of all its products in order to conduct an,internal ...
Cached Medicine Technology:FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 2Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 3
(Date:9/21/2014)... OH (PRWEB) September 21, 2014 C8 ... District of Ohio as the list of 20 possible ... been narrowed down to six, reports Wright & Schulte ... chosen from the almost 2500 C8 lawsuits filed that ... or testicular cancer as a result of being exposed ...
(Date:9/20/2014)... Recently, iFitDress.com, a well-known wedding dress manufacturer and retailer, ... . In addition, the company has launched a special offer ... is to benefit all of its big fans. Worldwide people ... , Along with beautiful party dresses, the company also ... released its new sexy short prom outfits and purple homecoming ...
(Date:9/20/2014)... Weight Destroyer , a weight loss ... Wren that has already helped tens of thousands of ... like high blood pressure, high cholesterol, and accelerated aging ... investigative review. , “Weight Destroyer is totally turning ... showing people what is truly effective when it comes ...
(Date:9/20/2014)... September 20, 2014 The Villa Group ... del Palmar Cabo San Lucas, Villa La Estancia and ... Hurricane Odile, with plans to welcome guests back to ... of Sept. 19, all members and guests of the ... to a coordinated effort with government authorities. , ...
(Date:9/20/2014)... NY (PRWEB) September 20, 2014 Ticket ... Grande concert tickets . This popular ticket exchange is ... , The 2015 schedule of tours is beginning ... have already announced their plans to hit the road, including ... Raton, Fla., announced the “Honeymoon Tour,” which will take her ...
Breaking Medicine News(10 mins):Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4Health News:Beautiful Party Dresses For Autumn Unveiled By iFitDress.com 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 3Health News:Villa Group Resorts in Cabo Largely Unharmed, Plan to Re-open Early October 2Health News:Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today 2Health News:Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today 3
... , ... and his foundation to raise money to help the people of Haiti. It is Mr. Kent and ... ... Capital, LLC., and CEO of the Kent Marketing Group to join forces with former NFL player Jack ...
... ... April 1 – May 30, people age 65 and older can call to determine if they ... ... of change, but don’t worry if you don’t have the change to spare for an eye ...
... The American Academy ... wrinkles that become etched into the surface of the skin and don,t disappear once you,re ... the face and the pillow, allowing the delicate facial skin, to remain smooth for the ... ...
... ... MDX/American Registry Medical Patient,s Choice Award. , ... (Vocus) March 30, 2010 -- Five Summit Medical Group physicians ... Gruber, M.D., Jed A. Kwartler, M.D., Eric Mrisky, M.D., and Monib Zirvi, M.D., join ...
... ... Processes, an internationally recognized leader in literacy research, remediation, and professional development, will ... campaign beginning April 1st, 2010. , ... San Luis Obispo, CA (Vocus) -- Lindamood-Bell ...
... Global Initiative (BHGI) and the Latin American & Caribbean ... biennial BHGI Global Summit on International Breast Health June ... international organizations to address the optimization of breast health ... 2010 Summit is "Optimizing Health Care Delivery." ...
Cached Medicine News:Health News:Thomas J. Kent Jr. FDP Capital, LLC Chairman and Former NFL Player Jack Brewer Join Forces 2Health News:EyeCare America Ushers in the New Season and Springs for Eye Exams for Qualified Seniors 2Health News:EyeCare America Ushers in the New Season and Springs for Eye Exams for Qualified Seniors 3Health News:Mumbani™ Fresh Face Pillow, an Anti-Aging and Anti-Wrinkle Sleep Accessory for Side and Stomach Sleepers! 2Health News:Mumbani™ Fresh Face Pillow, an Anti-Aging and Anti-Wrinkle Sleep Accessory for Side and Stomach Sleepers! 3Health News:Summit Medical Group Physicians Receive Patients' Choice Award 2Health News:Summit Medical Group Physicians Receive Patients' Choice Award 3Health News:Lindamood-Bell to Help Commemorate Autism Awareness Day 2Health News:Lindamood-Bell to Help Commemorate Autism Awareness Day 3Health News:Lindamood-Bell to Help Commemorate Autism Awareness Day 4Health News:The Global Summit on International Breast Health 2
... The AngioJet Xpeedior+120 Rheolytic Thrombectomy catheter is ... performance. Powerful saline jets create a low ... a vacuum effect. Thrombus is drawn into ... the jets, and removed from the body.,AngioJet ...
... CARTO XP Electroanatomical Mapping System combines the ... the operating ease of Windows* software. ... adding powerful new tools that enhance your ... takes you into the future of EP. ...
... generators are meeting the clinical needs ... and anesthesiologists. And, they are of ... from Medtronic.,Effective pacing with the adjustment ... for quick battery changes. Both ...
... Medtronic's temporary pulse generators are ... surgeons, nurses, cardiologists, electrophysiologists and anesthesiologists. ... and durability you expect from Medtronic.,Effective ... Reverse battery polarity for quick ...
Medicine Products: